Zenobia Therapeutics was founded in 2008 by Drs Vicki Nienaber and Robert Meadows. Zenobia’s founders are pioneers in the field of fragment-based lead discovery (FBLD) contributing to the model NMR screening paradigm, SARbyNMR (1,2) and inventing the first crystallographic screening method, CrystaLead (3).
Recognizing that diseases of the CNS are a significant unmet medical need, Zenobia Therapeutics quickly adapted the strengths of FBLD to address one of the biggest challenges of CNS drug discovery: finding leads that cross the blood-brain-barrier (BBB). The leading chemical properties for brain penetration include low molecular weight and clogP. So starting with small simple fragments and growing them systematically into small efficient leads seemed a strategic advantage in discovery of a CNS-directed therapeutic (4). Furthermore, data mining of historic clinical data showed that small simple compounds have a better chance of success in the clinic. This coined the phrase: “Start sm...
Welcome to our new blog. Here, we will be sharing thoughts and opinions based upon our 20-30 years of experience in fragment screening and structural biology. We will share data we have generated and significant findings that we feel apply to the structural biology and fragment screening field. We welcome your comments on the utility of our products, challenges you face in your research and your opionions on the field in general.
Zenobia Fragments became an official entity in 2013 as a forum for the growing products division of Zenobia Therapeutics (founded in 2008).
Our mission is to provide cutting edge products based on our experience and internal research. We provide products we have developed to accelerate Zenobia Therapeutics research and products developed and tested at Zenobia Fragments. By providing these products, we hope to advance research around the world and facilitate discovery of new treatments for unmet medical needs.